Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,479
Closed -$7.16K 3854
2025
Q4
$7.16K Buy
+1,479
New +$6.18K ﹤0.01% 2734
2023
Q3
Sell
-500
Closed -$984 3385
2023
Q2
$984 Buy
+500
New +$959 ﹤0.01% 2936
2021
Q4
Sell
-81
Closed -$1K 3111
2021
Q3
$1K Hold
81
﹤0.01% 2824
2021
Q2
$1K Sell
81
-260
-76% -$4.37K ﹤0.01% 2702
2021
Q1
$7K Hold
341
﹤0.01% 2054
2020
Q4
$9K Buy
341
+260
+321% +$5.83K ﹤0.01% 1817
2020
Q3
$1K Hold
81
﹤0.01% 2418
2020
Q2
$1K Sell
81
-419
-84% -$6.38K ﹤0.01% 2300
2020
Q1
$4K Sell
500
-787
-61% -$11.7K ﹤0.01% 1940
2019
Q4
$22K Hold
1,287
﹤0.01% 1351
2019
Q3
$13K Buy
1,287
+1,001
+350% +$13.5K ﹤0.01% 1555
2019
Q2
$4K Buy
+286
New +$5.11K ﹤0.01% 1884
2018
Q4
Sell
-205
Closed -$6K 2129
2018
Q3
$6K Hold
205
﹤0.01% 1635
2018
Q2
$5K Hold
205
﹤0.01% 1579
2018
Q1
$6K Buy
205
+60
+41% +$1.9K ﹤0.01% 1464
2017
Q4
$4K Hold
145
﹤0.01% 1636
2017
Q3
$3K Hold
145
﹤0.01% 1736
2017
Q2
$4K Buy
+145
New +$3.46K ﹤0.01% 1652

Other funds holding CLLS

Parallel Advisors's CLLS Position: Q1 2026 in Review

Parallel Advisors sold out of Cellectis (CLLS) in Q1 2026, closing a stake of 1,479 shares — an estimated $7.16K sold.

Parallel Advisors first reported a position in CLLS in Q2 2017 and held it in 18 quarters. The position peaked at $22K in Q4 2019. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.

  • Parallel Advisors reported no remaining Cellectis position as of Q1 2026 after selling out during the quarter.
  • Parallel Advisors sold 1,479 Cellectis shares in Q1 2026, an estimated $7.16K.
  • Parallel Advisors first reported a position in Cellectis in Q2 2017 and held it in 18 quarters.
  • Parallel Advisors's Cellectis position peaked at $22K in Q4 2019.
  • 32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.